Keywords: tarceva, improves, pfs, advanced, nsclc, usa, osi

Tarceva improves PFS 41% in advanced NSCLC

Article | 18 May 2009

Print This

The USA's OSI Pharmaceuticals presented positive, detailed results from the Phase III SATURN study of Tarceva (erlotinib) as a single ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in